FDA Accepts HeartBeam's 3D ECG System Into TAP Pilot; Pivotal Study Enrollment Set for Q1 2027
BEAT is trading near its 52-week low of $0.355 (14% above the low) on light trading volume (0.1× avg).
Summary
The FDA accepted HeartBeam's system into the Total Product Life Cycle Advisory Program (TAP) pilot, a regulatory fast-track channel that gives the company earlier and more frequent FDA feedback on its path to market. HeartBeam also said it expects to begin patient enrollment for its multicenter pivotal study in Q1 2027. This builds on the FDA Breakthrough Device Designation for the 3D ECG system reported in early October and follows the completed ALIGN-ACS enrollment disclosed in late September. For a micro-cap with a going concern warning and a $5.0 million quarterly net loss, regulatory momentum is the main lever on the story, though the pivotal study start is still months out and the company will need cash to fund it. Watch the Q1 2027 enrollment start and any financing ahead of it.
At the time of this announcement, BEAT was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.2M. The 52-week trading range was $0.36 to $4.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.